🇧🇪 UCB.BR — UCB SA

Salud Compra
← Volver

Precio actual

290,20 EUR

Máx. histórico

290,20

0 días

Caída desde máximo

En máximo

Rango 52 semanas

197,45 – 292,20

Variación hoy

+2,69%

Cierre anterior

282,60

Rango de hoy

282,40 – 292,20

Volumen hoy

256.291

Peor caída histórica

-66,30%

15/12/2006 → 27/10/2008

Recuperado en 1466 días

Volatilidad anualizada ⓘ

28,70%

Información
Nombre completo
UCB SA
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
9.000
PER ⓘ
25,64 (puede no estar actualizado)
Dividend yield
0,51% (puede no estar actualizado)
Precio objetivo analistas
291,58 EUR (puede no estar actualizado)
Primera cotización
04/01/2000
Precio actualizado
hace 7 horas
Sobre la empresa

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Dividendos repartidos Total últimos 12 meses: 1,4500 EUR · Yield: 0,50%
Fecha de pago Importe por participación
04/05/2026 1,4500 EUR
25/04/2025 1,3900 EUR
26/04/2024 1,3600 EUR
28/04/2023 1,3300 EUR
29/04/2022 1,3000 EUR
30/04/2021 1,2700 EUR
04/05/2020 1,2400 EUR
26/04/2019 1,2100 EUR
27/04/2018 1,1800 EUR
28/04/2017 1,1500 EUR
29/04/2016 1,1000 EUR
04/05/2015 1,0600 EUR
29/04/2014 1,0400 EUR
02/05/2013 1,0200 EUR
27/04/2012 1,0000 EUR
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
05/11/2024 178,75 183,80 178,70 179,45 +0,73% 2,85% 161.282
04/11/2024 179,45 181,30 177,60 178,15 -1,25% 2,06% 120.674
01/11/2024 176,80 180,85 176,80 180,40 +2,04% 2,29% 210.520
31/10/2024 178,60 178,60 175,80 176,80 -1,12% 1,57% 209.189
30/10/2024 180,15 181,40 177,30 178,80 -0,50% 2,28% 268.846
29/10/2024 178,00 181,40 177,80 179,70 +0,96% 2,02% 187.739
28/10/2024 178,25 179,55 177,20 178,00 -0,42% 1,32% 115.187
25/10/2024 175,70 180,55 175,70 178,75 +1,16% 2,76% 190.999
24/10/2024 174,20 177,65 173,75 176,70 +1,70% 2,24% 206.479
23/10/2024 171,10 173,85 171,05 173,75 +1,61% 1,64% 172.763
22/10/2024 173,05 173,45 169,95 171,00 -1,70% 2,02% 206.743
21/10/2024 173,40 175,90 172,70 173,95 +0,32% 1,85% 124.340
18/10/2024 175,60 176,05 172,00 173,40 -1,87% 2,31% 207.553
17/10/2024 171,65 176,70 171,65 176,70 +3,21% 2,94% 269.025
16/10/2024 173,45 173,90 170,25 171,20 -1,21% 2,10% 165.892
15/10/2024 173,30 174,80 172,40 173,30 +0,12% 1,38% 189.699
14/10/2024 171,35 174,15 171,05 173,10 +1,17% 1,81% 180.512
11/10/2024 167,25 172,40 167,25 171,10 +2,06% 3,08% 163.829
10/10/2024 167,30 170,95 167,00 167,65 +0,66% 2,36% 209.106
09/10/2024 167,00 167,75 163,90 166,55 -0,03% 2,31% 114.920
08/10/2024 165,45 166,95 164,85 166,60 +0,85% 1,27% 144.037
07/10/2024 166,65 167,20 164,60 165,20 -0,72% 1,56% 164.905
04/10/2024 165,00 167,20 164,20 166,40 +0,64% 1,82% 169.142
03/10/2024 164,35 165,35 162,25 165,35 +0,73% 1,89% 189.564
02/10/2024 164,20 165,35 162,90 164,15 -0,97% 1,49% 302.616
01/10/2024 162,65 167,05 162,40 165,75 +2,31% 2,86% 231.846
30/09/2024 160,60 163,50 160,30 162,00 +0,40% 1,99% 175.315
27/09/2024 162,75 163,55 160,30 161,35 -1,53% 2,00% 216.992
26/09/2024 169,05 169,20 162,60 163,85 -2,82% 3,90% 197.828
25/09/2024 166,25 168,85 165,50 168,60 +0,36% 2,02% 161.062